Proove BioSciences is developing a tool intended to help predict which patients will respond to medical detoxification. The genetic test and algorithm were studied in a trial involving 148 people.
Published in Brief:
|NGS Provider Enrollment Rep||
National Government Services - WellPoint
|Program Manager II||
Tufts Health Plan/Network Health
|Director, Medicare Advantage/Medicare Part D Focus||
|Chief, Product Review Branch||
FDA/Center for Biologics Evaluation and Research
|Silver Spring, MD|
|Director of Clinical Research||
Regenesis Biomedical, Inc.